SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

DelveInsight’s Diffuse Cutaneous Systemic Sclerosis Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging diffuse cutaneous systemic sclerosis drugs, ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

"Diffuse Cutaneous Systemic Sclerosis Pipeline"As per DelveInsight's assessment, globally, Diffuse Cutaneous Systemic Sclerosis pipeline constitutes 15+ key companies continuously working towards ...

Diffuse systemic sclerosis (dSSc) can be a devastating disease, and to date there are no clearly beneficial treatments. However, the agent relaxin has shown some promise in improving skin disease. [1] ...

Systemic sclerosis, or scleroderma, causes the hardening of skin and connective tissues. Often, the disease harms other organs, such as the heart, kidneys, lungs, and gastrointestinal tract, and it ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

Forty-six patients with scleroderma (3 male and 43 female) and 31 healthy controls (6 male and 25 female) were included in the study. Twenty-five patients had limited-type and 21 patients had ...

(MENAFN- GlobeNewsWire - Nasdaq) The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis ...